Home / Science / Virtual Cancer Twins Predict Treatment Success
Virtual Cancer Twins Predict Treatment Success
15 Aug
Summary
- Digital twins model patient cancers for treatment simulation.
- AI combines scans, data, and drug behavior for predictions.
- Theranostics advance precision cancer care using digital twins.
Nuclear medicine researchers are exploring the creation of "digital twins" for cancer patients, offering a virtual simulation of disease response to radioactive treatments. This innovative concept, detailed in "Digital Twins in Nuclear Medicine: A Pathway to Personalized Theranostics," proposes using computer models of individual patients to test various treatment scenarios virtually.
The digital twin would integrate a patient's scans, clinical data, and blood test results with artificial intelligence and models of radioactive drug behavior. This comprehensive approach aims to predict how a specific patient's cancer will react to therapy, potentially guiding doctors on the optimal dosage and highlighting risks to healthy organs.
This advancement builds upon theranostics, a precision cancer care method that uses molecular imaging to identify cancer cells and targeted radioactive medicines to treat them. For example, PSMA PET scans in prostate cancer pinpoint cancer cells, which can then be targeted with drugs like lutetium-177 PSMA.
While the technology is still in its research phase, it holds the promise of significantly improving cancer treatment. It could allow doctors to compare different therapeutic options on a patient's digital twin before initiating treatment, potentially leading to better outcomes and reduced side effects. The researchers emphasize that digital twins are intended to support, not replace, medical professionals, ultimately shifting cancer care towards proactive prediction of treatment success.
